S
INBX icon

Sanofi’s Inhibrx INBX Stock Holding History

Sanofi’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.8M Hold
1,157,926
– – 23.17% 2
2025
Q4 		$91.5M Hold
1,157,926
– – 29.47% 2
2025
Q3 		$39M Hold
1,157,926
– – 14.98% 3
2025
Q2 		$16.5M Hold
1,157,926
– – 9.4% 4
2025
Q1 		$16.2M Hold
1,157,926
– – 9.76% 3
2024
Q4 		$17.8M Buy
+1,157,926
New +$17.6M 10.23% 3

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sanofi's INBX Position: Q1 2026 in Review

Sanofi held its Inhibrx (INBX) position steady in Q1 2026 at 1,157,926 shares worth $77.8M. The position accounts for 23.17% of the portfolio, ranked #2.

Sanofi first reported a position in INBX in Q4 2024 and has held it in 6 quarters since. The position peaked at $91.5M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Sanofi held 1,157,926 shares of Inhibrx worth $77.8M as of Q1 2026.
  • Sanofi left its Inhibrx share count unchanged in Q1 2026.
  • Inhibrx made up 23.17% of Sanofi's portfolio in Q1 2026, its #2 holding.
  • Sanofi first reported a position in Inhibrx in Q4 2024 and has held it in 6 quarters since.
  • Sanofi's Inhibrx position peaked at $91.5M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Sanofi's 13F filing for Q1 2026, filed 7 May 2026.